On January 17, STADA Pymepharco – the sole wholly member of STADA Group (Germany) in Vietnam since 2021, officially launched the Vietnam Health Report 2024 at a Press Conference held at Deutshes Haus Ho Chi Minh City.
The event was organized by STADA Pymepharco, in collaboration with the Delegation of German Chamber of Commerce and Industry in Vietnam (AHK Vietnam).
The Vietnam Health Report 2024 offers key insights and analysis into the public’s satisfaction with the domestic public healthcare system, while also emphasizing the importance of Vietnam–Germany cooperation in improving healthcare quality.
The development and launch of this report reflect the company's on-going commitment to enhancing public health and and patient satisfaction in Vietnam through innovative healthcare solutions.
The Vietnam Health Report 2024 is part of the global STADA Health Report series, which has been conducted annually since 2014. The series aims to provide diverse, globally relevant analysis on a wide range of healthcare topics.
At the Press Conference, a representative of Phu Yen province remarked: "Phu Yen is home to STADA Pymepharco’s two EU-GMP-certified manufacturing facilities – a clear evidence of the province's commitment to innovation and international cooperation.
As a leading company in the province, STADA Pymepharco plays a key role in raising local healthcare standards locally while positioning Phu Yen as a strategic hub for pharmaceutical production".
Dr. Josefine Wallat - German Consul General in Vietnam, commented: "The Vietnam Health Report 2024 is a prime example of effective cooperation between Germany and Vietnam in the healthcare sector. By combining German expertise with local understanding, STADA Pymepharco plays a crucial role in addressing healthcare challenges and improving treatment outcomes".
Mr. Philippe Gautron - General Manager of STADA Pymepharco speaks at the press conference - Photo: DNCC
Mr. Philippe Gautron – General Manager of STADA Pymepharco emphasized: "The Vietnam Health Report 2024 demonstrates our commitment to bringing 'German standards' healthcare to Vietnam. Our ambition is to serve as a bridge for global innovation, enabling more Vietnamese citizens to access high-quality healthcare services.
With aspiration to expand our reach beyond Vietnam and strengthen our global presence – particularly in the European markets, we remain committed to providing ‘German standard’ healthcare. Backed by our two EU-GMP-certified manufacturing plants and a dedicated team of over 1,500 employees, STADA Pymepharco is positioned as a trusted partner in advancing community health.
At we embark on this exciting new chapter, we aim to build on our legacy of quality and innovation, foster meaningful partnerships, and deliver affordable, high-quality medicines to more communities worldwide. Together, we are shaping a future where healthcare knows no borders".
Guests attending the press conference to launch the Vietnam Health - Market Report 2024 - Photo: DNCC
Mr. Peter Kompalla – Chief Representative of AHK Vietnam also remarked: " STADA Pymepharco’s initiatives highlight the power of comprehensive partnerships, particularly in economic cooperation between Germany and Vietnam. By fostering such collaboration, we can unlock new opportunities to improve healthcare quality and expand access to high-quality medicines across Vietnam.
STADA Pymepharco, founded in 1989, was formerly known as Pymepharco. In 2021, STADA Pymepharco officially became the sole wholly-owned member of STADA Group (Germany) – one of the world’s leading pharmaceutical companies with nearly 130 years of history.
2024 marks a major milestone as STADA Pymepharco unveiled its refreshed corporate positioning and identity: Based on our purpose of “Caring for People’s Health as a Trusted Partner”, our aim is to provide “German standard” healthcare in Vietnam and to the world.
